Daxor Corp.
DXR - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$53.71M
Close$
$-0.02
100.2% downside
Current Fair Value
100.2% downsideOvervalued by 100.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $53.71 Million |
|---|---|
| Enterprise Value | $53.71 Million |
| Earnings per Share | $1.84 |
| Beta | 0.26 |
| Outstanding Shares | 4,985,286 |
Return
| Return on Equity | 15.48% |
|---|---|
| Return on Assets | 15.48% |
| Return on Invested Capital | 15.74% |
Valuation & Multiples
| P/E Ratio | 7.48 |
|---|---|
| PEG | 0.94 |
| Price to Sales | - |
| Price to Book Ratio | 0.9 |
| Enterprise Value to Revenue | 61.84 |
| Enterprise Value to EBIT | 6.58 |
| Enterprise Value to Net Income | 6 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
$2.80 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 10, 2027
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$7,573
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 9.32%▲ 0.89% |
|---|---|
| Total Invested | $4.77M▲ 17.33% |
| Investors Holding | 16▲ 2.00% |
About Daxor Corp.
Daxor Corporation is the global leader in blood volume measurement technology focused on blood volume testing innovation (organized as an investment company with fully-owned innovative medical instrumentation and biotechnology operations...